Drug Coatings
Drug Coatings - Related Videos
13:21
Graphene Coatings for Biomedical Implants
0 Views •
Cited by 37 •
2013
Graphene offers potential as a coating material for biomedical implants. In this study we demonstrate a method for coating nitinol alloys with nanometer thick layers of graphene and determine how graphene may influence implant response.
10:38
Synthesis of Functionalized 10-nm Polymer-coated Gold Particles for Endothelium Targeting and Drug Delivery
0 Views •
Cited by 8 •
2018
We describe a method of synthesizing biocompatible 10-nm gold nanoparticles, functionalized by coating poly-ethylene glycol onto the surface. These particles can be used in vitro and in vivo for delivering therapeutics to nanoscale cellular and extracellular spaces that are difficult to access with conventional nanoparticle sizes.
01:33
Coat Assembly and GTPases
0 Views •
2023
Vesicles incorporate different coat protein subunits in different cell locations, which changes the properties of the coat, such as the shape and geometry of the transport vesicles. Thus, vesicle coat proteins also play a significant role in cargo selection. Coat assembly depends on the local availability of phosphatidylinositol phosphates or PIPs and GTP-binding proteins. Adaptor proteins, which link the coat proteins to the membrane, bind to these PIPs and play a crucial role in controlling...
01:12
Clathrin Coated Vesicles
0 Views •
2023
Clathrin-coated vesicles use endocytosis to transport receptors and lysosomal hydrolases from the Golgi to the lysosome in the late secretory pathway. Clathrin-mediated endocytosis was the first described endocytic process, and Clathrin-coated vesicles remain one of the most well-studied transport vesicles. The molecular machinery that generates clathrin-coated vesicles comprises over 50 proteins that precisely coordinate vesicle formation. Cell surface receptors concentrated in indented sites...
00:59
COP Coated Vesicles
0 Views •
2023
Membrane-enclosed structures called vesicles transport proteins and lipids across the cell. The vesicles derive their cargo from the plasma membrane, Golgi, ER, or endosome. Coated vesicles are spherical, protein-coated carriers with a 50–100 nm diameter that mediate bidirectional transport between the ER and the Golgi. The distribution of proteins between the ER and Golgi complex is dynamic and is maintained by different coated vesicles. Their formation is driven by the assembly of different...
FAQs
Control depends on how the coating interacts with its surroundings and how the drug moves through its structure. A layer may dissolve, gradually erode, degrade, or regulate diffusion, producing different release patterns. Selecting among these behaviors helps align drug availability with the intended dosing schedule or delivery site, rather than allowing the entire dose to become available immediately.
Moisture, pH, enzymes, and time can act as release cues. A coating may respond by dissolving, degrading, eroding, or changing how readily the drug diffuses through the layer. These conditions matter because the same pharmaceutical agent can become available at different points in the body, supporting delayed release in an intended gastrointestinal region or another controlled delivery goal.
Composition and structure determine more than release speed. They also influence whether a layer protects the medicine, withstands the surrounding environment long enough to delay release, or permits gradual passage of the agent. This is why coating design must connect material behavior with the desired therapeutic performance, including stability, tolerability, and control of dosing.
For oral products, the coating can address several needs at once: masking an unpleasant taste, improving drug stability, and postponing release until a particular gastrointestinal region. Device coatings serve a different emphasis by supporting treatment at a localized site. The delivery context therefore determines whether protection, regional release, or local therapy is the primary objective.
Developing a coated medicine begins with matching the coating's composition and structure to the intended site and release rate. The relevant design question is whether the layer should dissolve, erode, degrade, or regulate diffusion under particular conditions. This alignment links formulation choices to the desired therapeutic performance instead of treating the coating as merely an external finish.
Drug coatings are used on tablets and capsules when administration requires better tolerability or more controlled exposure. Taste masking can make an oral product easier to take, while delayed release can direct availability toward a specified gastrointestinal region. These functions can improve dosing control and patient acceptance without changing the coating's central role in managing when the agent becomes available.
On implants and medical devices, a coating can support localized treatment by placing the pharmaceutical agent at the relevant site. The device context makes the intended location especially important, because release is associated with the coated implant or device. This strategy can contribute to therapeutic performance when treatment is meant to occur around that medical device.